Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas.

antibody–drug conjugates liposomes lymphoma magnetic resonance imaging nanomedicine nuclear imaging targeted drug delivery theranostics

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
26 Jan 2022
Historique:
received: 28 12 2021
revised: 17 01 2022
accepted: 24 01 2022
entrez: 15 2 2022
pubmed: 16 2 2022
medline: 16 2 2022
Statut: epublish

Résumé

Malignant lymphomas represent the most common type of hematologic malignancies. The first clinically approved TDD modalities in lymphoma patients were anti-CD20 radioimmunoconjugates (RIT)

Identifiants

DOI: 10.3390/cancers14030626 PMID: 35158894 PMC: PMC8833783
pubmed: 35158894
pii: cancers14030626
doi: 10.3390/cancers14030626
pmc: PMC8833783
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : Czech Science Foundation
ID : GACR19-01417S
Organisme : Czech Health Research Council
ID : AZV NU21-03-00386
Organisme : Charles University
ID : Center of Excellence UNCE/MED/016

Références

Leukemia. 2018 Aug;32(8):1768-1777
pubmed: 30030507
Molecules. 2018 Apr 14;23(4):
pubmed: 29662019
Hum Pathol. 2020 Jan;95:55-77
pubmed: 31493426
Mol Cancer Ther. 2021 May;20(5):885-895
pubmed: 33722857
Nano Lett. 2019 Jul 10;19(7):4213-4220
pubmed: 30719918
Adv Ther. 2017 Oct;34(10):2232-2273
pubmed: 28983798
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Adv Drug Deliv Rev. 2020;156:40-64
pubmed: 32735811
Blood Adv. 2021 Aug 24;5(16):3152-3162
pubmed: 34424320
Lancet Haematol. 2021 Jul;8(7):e481-e491
pubmed: 34171279
Blood. 2017 Oct 19;130(16):1800-1808
pubmed: 28774879
Methods Mol Biol. 2010;605:1-27
pubmed: 20072870
Am J Nucl Med Mol Imaging. 2020 Dec 15;10(6):334-341
pubmed: 33329935
Leuk Lymphoma. 2020 Oct;61(10):2502-2506
pubmed: 32508171
Lancet Oncol. 2014 Mar;15(3):275-85
pubmed: 24559803
J Clin Endocrinol Metab. 1949 Nov;9(11):1122-37, illust
pubmed: 15395978
J Control Release. 2018 Nov 10;289:44-55
pubmed: 30248447
Theranostics. 2017 Jun 11;7(9):2350-2362
pubmed: 28744319
Lancet Oncol. 2021 Jun;22(6):741-742
pubmed: 33989556
Onco Targets Ther. 2017 Oct 03;10:4821-4828
pubmed: 29042793
Lancet. 2016 Feb 20;387(10020):770-8
pubmed: 26673811
Am Soc Clin Oncol Educ Book. 2020 Mar;40:1-8
pubmed: 32223669
Mol Ther Nucleic Acids. 2014 Aug 05;3:e182
pubmed: 25093706
Chem Soc Rev. 2019 Aug 12;48(16):4361-4374
pubmed: 31294429
J Nucl Med. 2021 Aug 1;62(8):1025-1026
pubmed: 34330737
Front Pharmacol. 2015 Dec 01;6:286
pubmed: 26648870
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Br J Haematol. 2009 Jul;146(2):171-9
pubmed: 19466965
Bioconjug Chem. 2011 May 18;22(5):976-86
pubmed: 21452890
N Engl J Med. 2013 Aug 8;369(6):507-16
pubmed: 23782157
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1304-14
pubmed: 25792453
Int J Nanomedicine. 2019 May 23;14:3819-3830
pubmed: 31213803
Chem Rev. 2020 Apr 22;120(8):3787-3851
pubmed: 32202104
J Clin Oncol. 1997 Oct;15(10):3266-74
pubmed: 9336364
Pharmacol Ther. 2022 Jan;229:107917
pubmed: 34171334
N Engl J Med. 2018 Jan 25;378(4):331-344
pubmed: 29224502
Expert Opin Drug Deliv. 2018 Sep;15(9):893-903
pubmed: 30169978
Cancer Res. 2008 Nov 1;68(21):8643-53
pubmed: 18974103
N Engl J Med. 2005 Feb 3;352(5):441-9
pubmed: 15689582
N Engl J Med. 2021 Sep 16;385(12):1091-1103
pubmed: 34161051
Drug Deliv Transl Res. 2015 Jun;5(3):231-42
pubmed: 25787731
Nanomaterials (Basel). 2020 Feb 06;10(2):
pubmed: 32041219
Crit Rev Oncol Hematol. 2021 Jul;163:103377
pubmed: 34087342
Oncotarget. 2018 Apr 27;9(32):22316-22331
pubmed: 29854280
Drug Deliv. 2016 Nov;23(9):3319-3329
pubmed: 27145899
Clin Cancer Res. 2017 Oct 1;23(19):5858-5868
pubmed: 28630216
Blood. 1997 Sep 15;90(6):2188-95
pubmed: 9310469
J Clin Oncol. 2018 Sep 10;36(26):2684-2692
pubmed: 30024784
Drugs. 2020 Nov;80(16):1731-1737
pubmed: 32946059
Int J Nanomedicine. 2019 Oct 21;14:8321-8344
pubmed: 31695370
J Control Release. 2018 Apr 10;275:162-176
pubmed: 29448116
Bioconjug Chem. 1998 Jul-Aug;9(4):418-50
pubmed: 9667945
Pharmaceutics. 2017 Mar 27;9(2):
pubmed: 28346375
J Control Release. 2020 Dec 10;328:160-170
pubmed: 32860930
Blood. 2018 Feb 8;131(6):611-620
pubmed: 29158362
J Control Release. 2014 Aug 10;187:133-44
pubmed: 24874289
Clin Cancer Res. 2001 Jun;7(6):1490-6
pubmed: 11410481
J Clin Oncol. 2021 Oct 1;39(28):3109-3117
pubmed: 34170745
Med Health Care Philos. 2019 Dec;22(4):593-597
pubmed: 30976948
J Pers Med. 2021 Feb 10;11(2):
pubmed: 33578756
Cancer Sci. 2021 Jun;112(6):2426-2435
pubmed: 33792128
N Engl J Med. 2016 Aug 25;375(8):740-53
pubmed: 27292104
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Acta Biomater. 2020 Jan 15;102:13-34
pubmed: 31759124
Lancet. 2009 Mar 21;373(9668):1033-40
pubmed: 19304016
J Clin Oncol. 2010 Apr 10;28(11):1870-7
pubmed: 20212249
N Engl J Med. 2022 Jan 27;386(4):351-363
pubmed: 34904799
Lancet Oncol. 2021 Apr;22(4):512-524
pubmed: 33721562
Molecules. 2021 Sep 27;26(19):
pubmed: 34641391
Lancet. 2017 Aug 5;390(10094):555-566
pubmed: 28600132
Drugs. 2017 Sep;77(14):1603-1610
pubmed: 28819740
Med Oncol. 2002;19(1):55-8
pubmed: 12025891
J Clin Oncol. 2017 Jul 1;35(19):2125-2132
pubmed: 28441111
Adv Drug Deliv Rev. 2017 Jun 1;115:46-56
pubmed: 28433739
J Control Release. 2018 Oct 10;287:194-215
pubmed: 30165140
Drugs. 2018 Dec;78(18):1903-1910
pubmed: 30511323
Blood. 2018 Feb 8;131(6):589-590
pubmed: 29438968
Adv Sci (Weinh). 2021 Mar 15;8(10):2001879
pubmed: 34026426
Lancet Oncol. 2020 Jul;21(7):978-988
pubmed: 32511983
Clin Cancer Res. 2020 Sep 1;26(17):4521-4530
pubmed: 32499235
Mol Cancer Ther. 2021 May;20(5):896-905
pubmed: 33722858
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
J Control Release. 2012 Jun 10;160(2):117-34
pubmed: 22484195
J Control Release. 2013 Apr 28;167(2):210-8
pubmed: 23395689
N Engl J Med. 2017 Oct 5;377(14):1331-1344
pubmed: 28976863
Sci Transl Med. 2013 Oct 16;5(207):207ra144
pubmed: 24132639
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Lancet Oncol. 2021 Jun;22(6):790-800
pubmed: 33989558
Lancet. 2019 Jan 19;393(10168):229-240
pubmed: 30522922
ACS Appl Mater Interfaces. 2018 Sep 19;10(37):31114-31123
pubmed: 30141893
J Clin Endocrinol Metab. 1951 May;11(5):492-511
pubmed: 14832370
Adv Drug Deliv Rev. 2009 Nov 12;61(13):1177-88
pubmed: 19671438
Cancer Med. 2021 Feb;10(4):1314-1326
pubmed: 33492774
Oncologist. 2018 Sep;23(9):1103-1108
pubmed: 29650683
N Engl J Med. 2004 Mar 11;350(11):1079-80
pubmed: 15014180
Drug Discov Today. 2021 Nov 24;:
pubmed: 34838729
Theranostics. 2021 May 8;11(14):6966-6982
pubmed: 34093865
Blood. 2016 Dec 22;128(25):2931-2940
pubmed: 27815263
Mol Pharm. 2015 Jun 1;12(6):1798-812
pubmed: 25697404
Best Pract Res Clin Haematol. 2012 Jun;25(2):201-10
pubmed: 22687456
Blood. 2021 Jun 17;137(24):3365-3377
pubmed: 33512452
J Control Release. 2012 Jul 20;161(2):461-72
pubmed: 22094104
Br J Haematol. 2013 Sep;162(5):631-8
pubmed: 23802738
Eur J Cancer. 2016 May;58:112-21
pubmed: 26990931
Blood Cancer J. 2020 Aug 7;10(8):81
pubmed: 32769965
J Clin Oncol. 2012 Jun 20;30(18):2183-9
pubmed: 22454421
Lancet Haematol. 2020 Jun;7(6):e479-e489
pubmed: 32470439
Lancet Oncol. 2016 Mar;17(3):319-331
pubmed: 26899778
Cancer Genomics Proteomics. 2014 Mar-Apr;11(2):67-79
pubmed: 24709544
Theranostics. 2021 Jan 1;11(2):579-601
pubmed: 33391494
Clin Lymphoma Myeloma Leuk. 2014 Feb;14(1):37-42
pubmed: 24252360
Adv Healthc Mater. 2021 Mar;10(6):e2001382
pubmed: 33448122
J Clin Oncol. 2016 Apr 1;34(10):1104-11
pubmed: 26884582
J Clin Oncol. 2011 May 10;29(14):1803-11
pubmed: 21483013
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Nanomedicine (Lond). 2011 Feb;6(2):303-6
pubmed: 21385131
Anticancer Drugs. 2015 Mar;26(3):241-58
pubmed: 25415656
Blood. 2004 Mar 1;103(5):1807-14
pubmed: 14615373
J Clin Oncol. 2020 Jan 10;38(2):155-165
pubmed: 31693429
Br J Haematol. 2018 Aug;182(4):583-586
pubmed: 28677896
Drugs. 2018 Nov;78(16):1763-1767
pubmed: 30357593
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
Clin Cancer Res. 2020 Mar 1;26(5):1000-1008
pubmed: 31772119
N Engl J Med. 2020 Apr 2;382(14):1331-1342
pubmed: 32242358
Int J Nanomedicine. 2015 Feb 02;10:975-99
pubmed: 25678787
J Nucl Med. 2019 Jan;60(1):60-64
pubmed: 29777009

Auteurs

Tomas Etrych (T)

Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic.
ORCID: 0000-0001-5908-5182

Alena Braunova (A)

Institute of Macromolecular Chemistry, Czech Academy of Sciences, 162 06 Prague, Czech Republic.
ORCID: 0000-0001-9153-6502

David Zogala (D)

Institute of Nuclear Medicine, General University Hospital and First Faculty of Medicine, Charles University in Prague, 128 08 Prague, Czech Republic.
ORCID: 0000-0003-3372-1667

Lukas Lambert (L)

Department of Radiology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 128 08 Prague, Czech Republic.

Nicol Renesova (N)

First Faculty of Medicine, Institute of Pathological Physiology, Charles University, 121 08 Prague, Czech Republic.
ORCID: 0000-0003-4397-9469

Pavel Klener (P)

First Faculty of Medicine, Institute of Pathological Physiology, Charles University, 121 08 Prague, Czech Republic.
First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University in Prague, 128 08 Prague, Czech Republic.
ORCID: 0000-0001-7786-9378

Classifications MeSH